China Indicts British Man And American Woman In GlaxoSmithKline Spying Case
International Business Times
Published Jul 13, 2014 03:19PM ET
Updated Jul 13, 2014 03:30PM ET
China Indicts British Man And American Woman In GlaxoSmithKline Spying Case
By Dennis Lynch - Chinese authorities indicted a foreign couple Sunday for trafficking the personal information of Chinese citizens, the official Xinhua news agency reported.
Peter William Humphrey, 58, a British national, and Yu Ying Zeng, 61, an American woman, reportedly confessed to trading personal information after being arrested last August. The husband and wife team worked as private investigators looking into the large-scale Glaxosmithkline (LONDON:GSK) bribery scandal that broke in 2013.
The British drug giant allowed GSK China CEO Mark Reilly to hire the two former journalists via their self-owned investigative company ChinaWhys to find out who sent anonymous e-mails to GSK and the Chinese government alleging bribery at GSK and a sex tape of Reilly and a companion.
Reilly himself is accused of orchestrating massive systemic bribery throughout the company, totaling nearly $150 million illegally. He stepped down last July.
The couple allegedly traded “household registration details, background on family members, [and information on] real estate, vehicles, call log and exit-entry records,” Xinhua said.
They are the first foreigners indicted for private investigating in China. Of their 500 or so private investigations, at least 10 infringed on the privacy rights of Chinese citizens, prosecutors said. Humphrey admitted to buying personal information and following Chinese nationals to gather information. He told investigators he felt “betrayed and used” by GSK China and Reilly, who said the accusations in the anonymous e-mails were false. Humphrey has said, however, his investigation found the allegations to be true.
Get The News You Want
ChinaWhys states is mission is “to promote transparency, ethical business practices and international governance standards, to mitigate risk and reduce losses, in multinational operations in China and across Asia.”
The couple face a closed trial and diplomats were barred from seeing them in January. The couple’s son says he worries for his parents health. Humphrey suffers from arthritis and has been denied medication while Yu has been denied treatment for kidney trouble and her weight has reportedly fell to less than 90 pounds.
Xinhua, which is widely seen to speak for the Chinese government, called the GSK case “a warning to other multinationals in China that ethics matter.”
Written By: International Business Times
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.